Avacta Group Plc (OTCMKTS:AVCTF – Get Free Report) rose 2.1% on Friday . The company traded as high as $0.9550 and last traded at $0.9550. Approximately 3,000 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 24,927 shares. The stock had previously closed at $0.9355.
Avacta Group Stock Performance
The business’s 50 day simple moving average is $0.94 and its 200 day simple moving average is $0.95.
About Avacta Group
Avacta Group plc is a UK-based biotechnology company specializing in the discovery, development and commercialization of Affimer® biotherapeutics and diagnostic reagents. The company’s proprietary Affimer platform uses small, engineered protein scaffolds that can be tailored to bind specifically to target molecules, offering an alternative to traditional antibodies. Avacta operates two core divisions: Avacta Therapeutics, which focuses on novel treatments in oncology and immune-related diseases, and Avacta Analytical, which develops reagents and point-of-care diagnostic tests.
In its diagnostics business, Avacta has applied the Affimer technology to lateral flow assays, most notably for rapid detection of viral pathogens such as SARS-CoV-2.
Further Reading
- Five stocks we like better than Avacta Group
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
